Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.35 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6231085 | 0.91 | DRD2 (0.36) | DRD2SMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL6428071 | 0.83 | DRD2 (0.35) | DRD2SMN1; SMN2LMNAMAPT | |
| SCHEMBL5412204 | 0.79 | KDM4E (0.40) | DRD2MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL6232227 | 0.78 | ALDH1A1 (0.40) | DRD2HTTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5553593 | 0.77 | DRD2 (0.38) | DRD2LMNAMAPT | |
| SCHEMBL5554025 | 0.77 | GALR1 (0.38) | DRD2LMNAMAPT | |
| SCHEMBL4829587 | 0.76 | DRD2 (0.44) | DRD2MEN1KMT2ALMNAMAPT | |
| SCHEMBL6427798 | 0.76 | MEN1 (0.34) | MEN1KMT2AHTTDUSP3PTPN5 | |
| SCHEMBL6231918 | 0.76 | DRD2 (0.39) | DRD2MEN1KMT2ALMNAMAPT | |
| SCHEMBL6607362 | 0.76 | GALR1 (0.39) | DRD2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | DRD2 4763/4885MEN1 4510/4885KMT2A 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.